Here are the 10-K annual reports from Fortress Biotech, Inc. (FBIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow FBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIO filings page.
Fortress Biotech, Inc. is a biopharmaceutical holding and operating company that acquires, develops and monetizes drug assets through a network of subsidiaries and partner companies. It focuses on product revenue, equity stakes, dividends and royalties across dermatology, oncology, rare disease and gene therapy.
As of March 25, 2026, Fortress had 32,202,564 common shares and 3,427,138 shares of 9.375% Series A preferred stock outstanding, with non‑affiliate common equity valued at $43,741,728 as of its most recent second fiscal quarter. The company reports 78 full‑time employees across Fortress and its controlled entities.
Recent transactions reshaped the portfolio. Sun Pharma acquired former subsidiary Checkpoint, giving Fortress $28.0 million in cash plus potential royalties and up to $4.8 million tied to EU approval of UNLOXCYT. Cyprium’s Menkes disease therapy ZYCUBO won FDA approval, with up to $128 million in potential sales milestones and tiered royalties, and Cyprium sold its priority review voucher for $205 million. Additional upside comes from Journey’s launch of EMROSI for rosacea, an exclusive license for Avenue’s ATX‑04 in lysosomal storage diseases, Urica’s equity and royalty position in Crystalys’ Phase 3 gout program, and multiple late‑stage and mid‑stage programs in CMV vaccines, GBM CAR‑T, and other rare and neurological diseases.